Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMB-201
- Development stage
- Preclinical
- Lead developer
- Ambulero
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
AMB-201 is an investigational adeno-associated virus (AAV) gene therapy developed by Ambulero for the treatment of critical limb ischemia (CLI). The therapy utilizes a clinically tested AAV vector to deliver and over-express the gene for E-selectin (a cell adhesion molecule) directly into ischemic tissues. By increasing E-selectin levels, AMB-201 aims to restore damaged vascular tissues and promote repair in ischemic limbs, particularly in patients with diabetic co-morbidities who are at high risk for amputation. It is currently in preclinical development as part of a pipeline of E-selectin-based therapies for vascular diseases.
- Other names
- E-selectin AAV gene therapy
02
Targets
SELE (E-selectin)
Beyond the preview
Go deeper on AMB-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMB-201.